Jian Ding, Xiangchao Gu, Juan Zhang, WenQing Yang, and Qian Shi
Increasing evidence has shown that gut microbiota play an important role in shaping systemic immune response.
A growing number of studies have revealed how gut microbiota change immune response and influence the efficacy of anticancer immunotherapeutics, e.g. anti-CTLA-4 and anti-PD-L1 antibody treatment, both in laboratory and clinical settings.
The potential immuno-modulatory roles of gastrointestinal microbiota during preclinical immunotherapy evaluation have now been evaluated, focusing on anti-PD-1 treatment.
Your privacy is important to us.
We'll never share your information.